233 related articles for article (PubMed ID: 36879299)
1. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS).
Ahdi HS; Wichelmann TA; Pandravada S; Ehrenpreis ED
BMC Pharmacol Toxicol; 2023 Mar; 24(1):15. PubMed ID: 36879299
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).
Zhang X; Hamadeh IS; Song S; Katz J; Moreb JS; Langaee TY; Lesko LJ; Gong Y
J Bone Miner Res; 2016 Feb; 31(2):336-40. PubMed ID: 26288087
[TBL] [Abstract][Full Text] [Related]
3. A Summary of the Rare Reports of Osteonecrosis of the Jaw Associated With Tumor Necrosis-α Inhibitors in the United States Food and Drug Administration's Adverse Event Reporting System Database.
Wichelmann TA; Ahdi HS; Pandravada S; Ehrenpreis ED
J Oral Maxillofac Surg; 2023 Oct; 81(10):1311-1318. PubMed ID: 37480941
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals.
Neha R; Beulah E; Anusha B; Vasista S; Stephy C; Subeesh V
Int J Clin Pharm; 2020 Apr; 42(2):721-727. PubMed ID: 32270377
[TBL] [Abstract][Full Text] [Related]
5. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.
Peng J; Wang H; Liu Z; Xu ZL; Wang MX; Chen QM; Wu ML; Ren XL; Liang QH; Liu FP; Ban B
Front Pharmacol; 2022; 13():1017391. PubMed ID: 36339548
[No Abstract] [Full Text] [Related]
6. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
7. Review and update on drugs related to the development of osteonecrosis of the jaw.
Eguia A; Bagán-Debón L; Cardona F
Med Oral Patol Oral Cir Bucal; 2020 Jan; 25(1):e71-e83. PubMed ID: 31880288
[TBL] [Abstract][Full Text] [Related]
8. Medication-related osteonecrosis of the jaw: A literature review.
Kuroshima S; Sasaki M; Sawase T
J Oral Biosci; 2019 Jun; 61(2):99-104. PubMed ID: 31109863
[TBL] [Abstract][Full Text] [Related]
9. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
[TBL] [Abstract][Full Text] [Related]
10. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
11. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
13. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.
Kuroshima S; Sasaki M; Murata H; Sawase T
Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407
[TBL] [Abstract][Full Text] [Related]
14. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
15. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
O'Halloran M; Boyd NM; Smith A
Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
[TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.
Nicolatou-Galitis O; Kouri M; Papadopoulou E; Vardas E; Galiti D; Epstein JB; Elad S; Campisi G; Tsoukalas N; Bektas-Kayhan K; Tan W; Body JJ; Migliorati C; Lalla RV;
Support Care Cancer; 2019 Feb; 27(2):383-394. PubMed ID: 30353228
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
de Oliveira CC; Brizeno LA; de Sousa FB; Mota MR; Alves AP
Med Oral Patol Oral Cir Bucal; 2016 Jul; 21(4):e431-9. PubMed ID: 26827069
[TBL] [Abstract][Full Text] [Related]
18. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
Yarom N; Lazarovici TS; Whitefield S; Weissman T; Wasserzug O; Yahalom R
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan; 125(1):27-30. PubMed ID: 29102242
[TBL] [Abstract][Full Text] [Related]
19. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.
Querrer R; Ferrare N; Melo N; Stefani CM; Dos Reis PED; Mesquita CRM; Borges GA; Leite AF; Figueiredo PT
Support Care Cancer; 2021 Jun; 29(6):2811-2820. PubMed ID: 33140246
[TBL] [Abstract][Full Text] [Related]
20. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.
Schiodt M; Vadhan-Raj S; Chambers MS; Nicolatou-Galitis O; Politis C; Coropciuc R; Fedele S; Jandial D; Zhang J; Ma H; Saunders DP
Support Care Cancer; 2018 Jun; 26(6):1905-1915. PubMed ID: 29275525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
